TuHURA Biosciences Issues 1.88M Shares Related to $50M Loan

What Happened

• TuHURA Biosciences filed an 8-K (Aug 19, 2026) reporting that, per a Loan Agreement and Fee Letter dated April 21, 2026, it will issue 1,878,287 shares of common stock to Parkview Holdings One LLC as a fee in connection with a $50 million revolving credit facility.
• The issuance follows stockholder approval at the company’s 2026 Annual Meeting and will be completed as an unregistered private placement to an accredited investor.

Key Details

• Loan facility: $50 million revolving credit extended by Parkview Holdings One LLC (Loan Agreement dated April 21, 2026).
• Fee paid in stock: 1,878,287 shares of TuHURA common stock (the “Loan Fee Shares”).
• Stockholder approval: issuance approved at the 2026 Annual Meeting of Stockholders.
• Registration/exemption: Company intends to rely on Securities Act Section 4(a)(2) and/or Regulation D (Rule 506) and applicable state law exemptions for the private issuance.

Why It Matters

• The company used equity (shares) rather than cash to pay a financing fee, which increases shares outstanding and dilutes existing shareholders to that extent.
• The revolving credit facility provides liquidity up to $50 million; the issuance documents the cost of securing that facility and the counterparty (Parkview).
• The transaction was approved by shareholders and structured as a private placement to an accredited investor, so no new public registration of these shares was required.